Podcasts about multidisciplinary association

In this interview from 1977, Ram Dass shares his views on psychedelics and how they can provide a free slate to experience the innocence of consciousness once again. Join the most important psychedelic gathering of the year......bridging science, spirit & society at Psychedelic Science 2025: THE INTEGRATION, hosted by the Multidisciplinary Association for Psychedelic Studies. Be part of the movement that will shape the next era of mental health, medicine, and consciousness.Featuring speakers like Paul Stamets, United States Representative Tim Ryan, UCSF Neuroscience & Psychopharmacology Researcher Robin Carhartt-Harris, Rick Doblin, founder of Internal Family Systems (IFS) Richard Schwartz, Pilar Guzman, CEO/Medical Director of the American Psychiatric Association Marketa M. Wills - M.D., M.B.A., FAPA, Raghu Markus, comedian Reggie Watts, musicians TYCHO & Jim James, and many more!Listeners get 15% off tickets to the 5-day event with our promo code LSRF15 at PsychedelicScience.orgThis episode of Here and Now is from an interview with Ram Dass conducted by New Dimensions Radio in 1977, shortly after Ram Dass participated in a conference called “LSD – A Generation Later.” The interview begins with Ram Dass discussing the happenings at the conference and his interactions with other psychedelic luminaries, including Timothy Leary, Ralph Metzner, and Albert Hofmann. Ram Dass explores the culture surrounding LSD in 1977, and how he has no desire to legislate how other people live their lives. He shares his guru's instructions for using the “yogi medicine” and talks about whether or not it's important to have a guide for psychedelic experiences.Finally, Ram Dass cautions that “getting high and seeing” is only one part of the process of change, and there are inner processes necessary to bring about change in life. He discusses the cultural evolution brought about by psychedelics and the shifts in consciousness he sees taking place. The Ram Dass community gathers regularly to engage in meaningful discussions about the podcast. We invite you to join us and share your curiosities, insights, and wisdom. Sign up for the General Fellowship to receive event invitations directly in your inbox.Sponsors of this Episode:This show is sponsored by Magic Mind, a matcha-based energy shot infused with nootropics and adaptogens designed to crush procrastination, brain fog, & fatigue. Check out their new Maxx & Free energy shots and get 60% off your subscription with our code RAMDASS60 at magicmind.com/ramdassmfRam Dass Here & Now is also brought to you by BetterHelp. Give online therapy a try at betterhelp.com/ramdass and get on your way to being your best self.Reunion is offering $250 off any stay to the Love, Serve, Remember community. Simply use the code BeHere250 when booking. Disconnect from the world so you can reconnect with yourself at Reunion. Hotel | www.reunionhotelandwellness.com Retreats | www.reunionexperience.org“If you have a guide, you're calm, and you really want to explore your inner being, I still see LSD as an incredible vehicle for overriding your habitual response patterns, your habits of thought, and giving you a free slate to experience your innocence of consciousness once again.” – Ram DassSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Neuroscientist Gül Dölen explores how psychedelics paired with mindful integration can reopen the brain's sensitive learning windows to rewire habits, heal trauma, and expand consciousness.Join the 2025 MAPS conference this June in Denver, Colorado and be a part of the movement that will shape the next era of mental health, medicine, and consciousness. MAPS, The Multidisciplinary Association for Psychedelic Studies, is a nonprofit organization that provides public resources and leadership as we work together to create legal, responsible, evidence-based pathways to psychedelics. Learn more about the conference and use the coupon code LSRF15 for a special promotion at https://www.psychedelicscience.orgIn this episode of Mindrolling, Gül and Raghu chat about: Gül's research on psychedelics and how we can translate animal studies into human neuroscience Looking to Octopuses for sociological answers using MDMACritical periods—windows when the brain is most open to learning and environmental influence.Psychedelics as the master key to reopening critical periods, especially when paired with therapyInducing metaplasticity with psychedelics, reshaping harmful patterns, and promoting transformation.Non-substance methods to reopen critical periods, like sensory and social deprivationHow mystical practices such as meditation and silent retreats can trigger a “beginner's mind” state for deep insightsHow psychedelics propose a learning model rather than a biochemical imbalance model towards approaching depression, addiction, or PTSDFocusing on post-trip integration to harness long-term benefits from the psychedelic experience Maximize the integration period to cement insights gained during psychedelic journeysThe social and psychological changes we go through as we age and adapt to new environments/situations The importance of “set and setting” and how it can influence psychedelic experiences and the formation of helpful or harmful habitsMindrolling is brought to you by Reunion. Reunion is offering $250 off any stay to the Love, Serve, Remember community. Simply use the code “BeHere250” when booking. Disconnect from the world so you can reconnect with yourself at Reunion. Hotel | www.reunionhotelandwellness.com Retreats | www.reunionexperience.orgAbout Gül Dölen:Dr. Gül Dölen is a Professor and the Bob & Renee Parsons Endowed Chair in the Department of Neuroscience, and Department of Psychology, the Berkeley Center for the Science of Psychedelics and the Helen Wills Neuroscience Institute at the University of California, Berkeley. Dr Dölen also maintains an Adjunct Professorship in Neuroscience and Neurology at the Johns Hopkins University, School of Medicine. Dr. Dölen researches the role psychedelics may have in unlocking critical periods in Dölen Lab. She is the recipient of several prestigious awards. “It turns out that our results really suggest that psychedelics are those master keys that we have been looking for all this time.” – Gül DölenSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Christina Kantzavelos is a neurodivergent, and first-generation (third culture) Licensed Clinical Social Worker (LCSW), life coach, writer and chronic illness warrior.  She received both her BA and MSW from the University of California Los Angeles (UCLA) and her MLIS from San Jose State University (SJSU). She specializes in treating clients with chronic health conditions  (aka spoonies and medical refugees) and trauma (including medical trauma). Rick Doblin, Ph.D., is the Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients.His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary's Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner.His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and puppy, with three empty rooms from his children who have all graduated college and begun their life journeys. Learn more about Rick by listening to his Origin Story, watching his TED Talk, and watching his SSDP talk about lessons for political activism from a series of his psychedelic experiences. In This EpisodeChristina's websiteNeural Retraining informationConstructed AwarenessRick's InstagramMAPS WebsiteYou can learn more about what I do here:The Trauma Therapist Newsletter: celebrates the people and voices in the mental health profession. And it's free! Check it out here: https://bit.ly/4jGBeSaThe Trauma Therapist Podcast:  I interview thought-leaders in the fields of trauma, mindfulness, addiction and yoga such as Peter Levine, Pat Ogden, Bessel van der Kolk and Bruce Perry. https://bit.ly/3VRNy8zBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-trauma-therapist--5739761/support.

Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit established in 1986 to advance evidence-based psychedelic therapy and end prohibition. MAPS incubated Lykos Therapeutics (formerly MAPS Public Benefit Corporation) which is leading drug development of MDMA-assisted therapy for PTSD.  Learn more about Psychedelic Science 2025, June 16–20 at the Colorado Convention Center in Denver, at www.psychedelicscience.org, and visit www.maps.org for information on MAPS Learn more about your ad choices. Visit podcastchoices.com/adchoices

Working with partners in government, business, and the community, MAPS Canada is committed to advancing psychedelic medicine by supporting scientific, multidisciplinary research; advocating for drug policy reform; offering public education; and supporting equitable access to legal and regulated psychedelic medicine in Canada. The Multidisciplinary Association for Psychedelic Studies (MAPS) was formed in the US in 1986, in response to the US Drug Enforcement Agency's classification of MDMA as Schedule 1 substance, and has been developing medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics since then. MAPS Canada was founded as a sister organization to MAPS in 2011, and is a registered Canadian non-profit organization. Based in Vancouver and with hundreds of volunteers from across Canada, MAPS Canada is moving forward to become the leading Canadian source of information, resources and advocacy regarding psychedelic medicine and related clinical research, education, and public policy. Learn More at https://mapscanada.org/about/ MAPS Canada is entirely funded by public donation and your support really makes a difference. Find out about all the ways you can support MAPS Canada's mission by visiting our donation link https://mapscanada.org/donate/ Many ways to engage, join our community: / mapscanada / mapscanada / mapscanada

Episode SummaryThe highly informed and deeply compassionate Amy Emerson joins Jef Szi and the How Humans Work Podcast for a remarkable conversation about the evolving landscape of psychedelics. With her extensive involvement and leadership in the Multidisciplinary Association of Psychedelic Studies (MAPS)* and their multi-year effort to get MDMA approved by FDA as a therapeutic medicine for PTSD. There are few better than Amy who can speak to the state of psychedelics for medical use in society. Not only does Amy share her honest appraisal about FDA drug approval process and members of congress on the Hill, she gives us the little known and fascinating history of MDMA. Some highlights are Sasha and Ann Shulgin's groundbreaking contributions, the reputational damage MDMA suffered in the 90's, the long-game efforts of Rick Doblin and others, the powerful way MDMA works on the brain, and the remarkable promise MDMA has shown to help people suffering with PTSD. Put together as a whole, Emerson offers us a destigmatized and inspiring view of MDMA beyond the common street descriptions of Ecstasy and Molly. From MDMA and the Medical Model, Amy then helps us see the many other use-cases for psychedelics that have a long and varied history. Building on issues of trauma and the importance of spiritually reconnecting with ourselves, we walk through the psychological benefits that can come with right-use of psychedelics.Finally, this conversation opens the visions of what future of psychedelic use in society through thoughtful contexts that track safety concerns and how, much like meditation, these ‘medicines' can have a place in our society like Buddhist and meditation practices have entered our culture. All in all, Breaking the Stigma is a podcast of significance, as it invites us to reconsider our biases around psychedelics at a time when our society is challenged by mental health matters like trauma and the pervasive disconnection from nature and spiritual renewal. ***** About: Amy Emerson is a highly respected leader in the field of psychedelic-assisted therapy. She was Lykos Therapeutics (formerly MAPS PBC) CEO for an important period in advancing MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) as a drug with the FDAShe earned a Bachelor of Science in Genetics and Cell Biology from Washington State University and spent the early career involved in roles at pharmaceutical companies, where she contributed to the development of therapies in immunology, oncology, and vaccines .​In 2003, she began volunteering with the Multidisciplinary Association for Psychedelic Studies (MAPS), assisting with clinical research monitoring. Her expertise was instrumental in establishing MAPS' clinical department and managing the MDMA Clinical Development Program. When MAPS founded its Public Benefit Corporation (MAPS PBC) in 2014 to develop and commercialize MDMA-assisted therapy, Emerson was appointed CEO .​Under her leadership, the organization, later rebranded as Lykos Therapeutics, completed multiple Phase 2 and Phase 3 clinical trials and raised approximately $150 million in funding. The company grew to over 120 employees, all working toward the goal of obtaining FDA approval for MDMA-assisted therapy for PTSD .​Amy resigned form her CEO role in September 2024. Currently she is a senior advisor to Lykos and an independent psychedelic research consultant, awaiting the next big adventure.*****Chapters00:00 Introduction and Setting the Stage02:40 The Evolution of Psychedelic Research06:10 Understanding Stigma and Its Origins10:54 MDMA: From Therapy to Recreation16:33 Therapeutic Applications of MDMA20:28 Navigating the FDA and Drug Development24:45 Challenges

Ben "Doc" Askins is a multifaceted professional with a rich background in both military service and mental health care. He holds degrees in Outdoor Education, Intercultural Studies, Physician Assistant Studies, and a Master of Divinity. During his nearly two-decade military career, he practiced and taught wilderness, tactical, and expeditionary medicine. In his civilian role as a Psychiatric Physician Assistant, Ben adopts an integrative approach to mental health, specializing in ketamine-assisted psychotherapy, medication management, and spiritual direction. He is certified by the Multidisciplinary Association for Psychedelic Studies (MAPS) in MDMA-assisted psychotherapy. Ben is the author of "Anti-Hero's Journey: The Zero With a Thousand Faces," a book that serves as both a memoir and a philosophical exploration. The work challenges traditional narratives of the "hero's journey," offering readers a unique perspective on self-discovery and personal growth. In addition to his writing, Ben hosts the "Anti-Hero's Journey" podcast, where he engages in thought-provoking discussions on topics ranging from trauma and empathy to unconventional healing methods. His episodes often delve into the complexities of the human experience, providing listeners with insights into overcoming personal challenges. Ben's expertise in ketamine-assisted psychotherapy is a cornerstone of his practice. He has conducted numerous sessions focusing on treating depression, PTSD, and acute suicidality. His commitment to innovative mental health treatments is evident in his clinical work and ongoing research.

The breakthroughs we're seeing in psychedelic medicine today started with non-profit organizations taking risks that others wouldn't.Three organizations leading the charge are Multidisciplinary Association for Psychedelic Studies (MAPS), OPEN Foundation and Champalimaud Foundation.Psychedelic research faces unique hurdles, such as Schedule I drug classification, complex regulatory requirements, and historical stigma. Traditional funding sources (pharma, government and academia) often avoid these high-risk, long-term investments, which is where non-profits can make big strides. They tend to be mission-driven, patient-focused, and have a long-term commitment to research.Check out my latest Nina's Note to learn how these organizations push psychedelic research forward and act as bridge-builders between science and public understanding.

Dr. Rick Doblin, founder of Multidisciplinary Association for Psychedelic Studies (MAPS), and Jeff Zucker discuss activism, psychedelics, epigenetics, generational trauma, and more. Watch this episode on YouTube https://youtu.be/xlsVDPRvDtE Chapters: 0:00 - Intro 2:34 - People are the Answer 4:37 - Put it Into Practice 5:56 - Intention 10:24 - Fear and Motivation 12:05 - What Motivates You? 19:45 - How Relatives Coped with the Holocaust 24:36 - Epigenetics of Trauma 26:29 - Giving Back in Early Life 33:43 - Global Spirituality 39:49 - What Lead to Starting MAPS? 52:44 - How Do We Move Forward with MDMA? 57:08 - State Level an Option? 1:00:28 - MAPS Cannabis Project 1:02:18 - Medical Cannabis in SC 1:05:02 - How Do You Avoid Burnout? 1:07:18 - What is MAPS Working on Now? 1:11:04 - Oregon Recriminalization 1:13:17 - Snap Your Fingers 1:15:26 - How to Support Rick Doblin: https://www.linkedin.com/in/rickdoblin/ https://www.instagram.com/rickdoblinphd/ MAPS: https://maps.org/ https://www.linkedin.com/company/mapsnews/ https://www.instagram.com/maps__org/ https://www.facebook.com/mapsmdma https://twitter.com/MAPS https://www.youtube.com/c/mapsmdma https://www.reddit.com/user/MAPSPsychedelic/?rdt=36196 Host: Jeffrey M. Zucker Producer: Kait Grey Editor: Nick Case Recording date: 12/3/24

In this episode of the MindHack Podcast, we sit down with Ben "Doc" Askins, a former combat medic turned psychiatric physician assistant, who brings a wealth of experience in trauma therapy and unconventional healing. With nearly two decades in military medicine and a specialization in psychedelic-assisted psychotherapy, Ben challenges the traditional Hero's Journey narrative and instead explores the path of the Anti-Hero—a journey that delves into the raw, real, and often messy truths of self-discovery. Through his unique insights, Ben shares how confronting trauma and embracing empathy are essential for true healing.This conversation is for anyone grappling with their own inner battles or seeking to make peace with past traumas. Together, we uncover practical steps to break free from self-deception, build meaningful connections, and find empathy not only for others but also for ourselves. Join us as we unpack a new approach to healing—one that is unfiltered, authentic, and ultimately empowering. ℹ️ About this Guest Ben "Doc" Askins is a former combat medic and psychiatric physician assistant with nearly two decades of experience in trauma care and therapy. Certified in MDMA-assisted psychotherapy by the Multidisciplinary Association for Psychedelic Studies (MAPS), Ben blends traditional medicine with innovative approaches to healing. As the author of Anti-Hero's Journey: The Zero With a Thousand Faces, he challenges conventional narratives of growth, offering raw insights on trauma, empathy, and self-discovery. Through his work, Ben inspires others to confront their struggles and embrace authentic transformation.WebsiteClinical WebsiteFacebook PageYouTubeTwitterInstagramListen on Apple PodcastListen on SpotifyDownload as an MP3 - https://bit.ly/3B3UXKnAnti-Hero's Journey: The Zero With a Thousand Faces: A Warped War Memoir on the Way to Enlightenment By Ben "Doc" Askins 

Ospite della 131° puntata di Illuminismo Psichedelico è Rick Doblin, fondatore e presidente della Multidisciplinary Association for Psychedelic Studies (MAPS) ed ex membro del consiglio di amministrazione di Lykos Therapeutics. Insieme a Doblin abbiamo parlato della sua scoperta e del suo rapporto con l'MDMA, di come questo abbia ispirato la nascita di MAPS e le ricerche per consentire un uso terapeutico della sostanza, ma anche di come poi le cose siano andate male, a causa della concorrenza di altre entità che chiedevano fondi per ricerche sugli psichedelici MAPS è stata costretta a generare una costola "for profit", Lykos, che ben presto è diventata un "lupo tra i lupi", e Doblin ha deciso di lasciarla, mostrandosi molto critico con come la nuova entità ha scelto di comunicare ma anche di difendere i risultati della fase 3 dei trial sull'MDMA, bocciati nella scorsa estate dalla FDA. 

Subscribe, Rate, & Review Future Fossils on YouTube • Spotify • Apple PodcastsThis week on Future Fossils I welcome back Sara Phinn Huntley (help her fight cancer!), a multimedia artist, writer, and researcher who has spent the last two decades exploring the intersection of psychedelics, technology, and philosophy.An intrepid psychonaut and cartographer of hyperspace, her current focus involves using VR to represent visual/spatial imagination in real-time. Using a multidisciplinary approach, she documents and maps the states revealed by dimethyltriptamime and other psychedelics, cargo culting higher dimensional artifacts through the intersection of chaos mathematics, Islamic geometry, and 3D diagrammatic performance capture.  Her work has been published by the Multidisciplinary Association of Psychedelic Studies and featured in Diana Reed Slattery's Xenolinguistics. She is the art director for The Illustrated Field to the DMT Entities with David Jay Brown (forthcoming at Inner Traditions, 2025).✨ Offer Support + Join The Scene• Become a patron on Substack or Patreon• Make a tax-deductible donation to Humans On The Loop• Invite me to work with you as an hourly consultant or advisor on retainer• Join the Holistic Technology & Wise Innovation and Future Fossils Discord servers• Join the Future Fossils Facebook group• Buy the books we discuss from my Bookshop.org reading list• Buy original paintings and prints or commission new work• Tip me with @futurefossils on Venmo, $manfredmacx on CashApp, or @michaelgarfield on PayPal• Buy the show's music on Bandcamp — intro “Olympus Mons” from the Martian Arts EP & outro “Sonnet A” from the Double-Edged Sword EP✨ Main Points + Big Ideas* The Entanglement of Language and Being: DMT entities reveal a profound connection between language and the construction of reality, echoing themes found in esoteric traditions and the emergence of AI.* The Cartography of Hyperspace: The book serves as a guide to the vast and uncharted territory of DMT experiences, highlighting the challenge of classifying subjective encounters and the potential for mapping a multidimensional reality.* The Reproducibility Problem and the Power of Big Data: While acknowledging the inherent challenges of studying subjective experiences, we point to the potential of emerging technologies like AI, blockchain, and large-scale data analysis to offer new insights.* Embodied Bias and the Nature of Evolution: The nonlinear and multidimensional nature of DMT experiences challenges our understanding of time, evolution, and even anatomy, prompting a re-evaluation of our assumptions about reality.* Attention as a Currency: We emphasize the importance of attention in navigating both the DMT space and the rapidly evolving technological landscape, posing critical questions about who or what deserves our focus.* The Question of Human Survival: The episode ends by urging humanity to confront its self-destructive tendencies and leverage its collective wisdom to navigate the challenges and opportunities of the future.✨ ChaptersChapter 1: Sara's Psychedelic Journey and the Genesis of the DMT Entities Field Guide (00:00:00 - 00:10:00)* Sara's fascination with DMT from a young age.* Her exploration of DMT through various artistic media, including performance art and xenolinguistics.* The inception of The Illustrated Field Guide to DMT Entities book, inspired by classic field guides to nature.* The decision to leverage AI in the book's creation due to the vastness of the subject matter.Chapter 2: Language, Being, and the AI Oracle (00:10:00 - 00:20:00)* The role of language in shaping and interpreting DMT entities, drawing parallels to esoteric traditions like the concept of the Logos.* Sara's process of interacting with AI, describing it as "talking to it" to curate the visual representations of DMT entities.* The blurring of categories and the subjective nature of interpreting the raw data of DMT experiences.* The challenge of reconciling diverse and often conflicting perceptions of the same entities.* Language as a compression tool for expressing ineffable experiences.* The increasing relevance of AI in understanding consciousness, particularly with future advancements in brain modeling.Chapter 3: Navigating Ontological Shock and the Nature of DMT Entities (00:20:00 - 00:30:00)* The challenge of reconciling DMT experiences with our "meat space" understanding of reality.* Sara's personal experience of gaining knowledge through DMT, challenging James Kent's view on the limitations of such knowledge.* The neurological basis for some common DMT hallucinations and its implications for understanding the experience.* The interplay of cultural and personal projections in shaping DMT entity encounters.* Exploring the possibility of psychedelics as a way to interact with a simulated reality.* The existence of phenomena that defy current scientific understanding, pointing to the need for open-mindedness.Chapter 4: The Cartography of Hyperspace and the Specter of Evolution (00:30:00 - 00:40:00)* The possibility of DMT entity encounters revealing more about the observer than about independent beings.* The existence of consistent archetypes across different DMT experiences and their overlap with other paranormal phenomena.* The intriguing connection between DMT entities and cross-cultural mythological figures.* Examining the role of genetic lineage and the intergenerational transmission of unusual experiences.* The book as a tool for intellectual curiosity, humility, and exploring the vastness of hyperspace.* The influence of culture in shaping our perceptions of both traditional and modern entities.* Sara's personal stance on the reality of DMT entities - acknowledging their potential existence while remaining open to other interpretations.Chapter 5: The Machine in the Ghost: Folklore, AI, and the Urge to Classify (00:40:00 - 00:50:00)* The blurring lines between insectoid and mechanical entities in both folklore and modern UAP narratives.* The impact of technology and the idea of a simulated reality on our perception of entities.* Sara's view on the potential taxonomic shift in our understanding of entities due to technological advancements.* Exploring the limits of AI in understanding consciousness and the potential for using it as a tool for self-reflection.* The challenge and importance of maintaining a sense of awe and wonder amidst scientific inquiry.Chapter 6: The Problem of Reproducibility and the Potential of Big Data (00:50:00 - 01:00:00)* Acknowledging the inherent limitations of scientific inquiry into subjective experiences.* The promise of machine learning and big data in identifying patterns and correlations across diverse DMT experiences.* The potential for reconstructing visual fields from brain data to gain further insights into the DMT experience.* The potential for utilizing blockchain technology, quadratic voting, and other advanced tools to address researcher bias and context in large-scale data collection.Chapter 7: Embodied Bias and the Non-Linearity of Time (01:00:00 - 01:10:00)* The idea of anatomy as an encoded representation of environmental features and its implications for understanding non-human entities.* Challenging the linear concept of time and evolution in light of the multidimensional experiences offered by DMT.* The vastness and complexity of "meat space" reality and its potential to hold hidden dimensions and Easter eggs.* The potential for AI and advanced computation to unlock deeper understanding of reality in conjunction with psychedelic exploration.Chapter 8: Sara's Breakthrough Experience and the Reverence for Mystery (01:10:00 - 01:20:00)* A detailed description of the experience, including encountering cloaked entities, a 12-dimensional brain diagnostic tool, and a neurosurgeon-like being.* The intensity and reality-shattering nature of the experience, surpassing previous encounters with DMT entities.* Sara's decision to take a break from psychedelics after this experience.* The importance of reverence and respect when engaging with the DMT space and its mysteries.* The continuing potential for breakthroughs and the limitlessness of the DMT rabbit hole.Chapter 9: Attention, AI, and the Question of Human Survival (01:20:00 - 01:30:00)* The book as a shared tapestry of experiences, honoring the work of other artists and researchers.* The importance of acknowledging both shared archetypes and individual variations in DMT experiences.* The potential for AI to evolve beyond human comprehension and the need for humans to adapt.* The question of AI's attention span and its potential implications for human-AI interaction.* The need for humanity to overcome its self-destructive tendencies in order to harness the potential of technology and navigate the future.* Sara's personal mission to inspire progress and wonder through her art.✨ Mentions* David Jay Brown - Author of The Illustrated Field Guide to DMT Entities* Diana Reed Slattery - Author of Xenolinguistics* Ralph Abraham - Chaos theoretician at UCSC who taught Sara about wallpaper groups* James Kent - Author of Alien Information Theory* Aldous Huxley - Author of the essay "Heaven and Hell"* K. Allado-McDowell - Co-director of Google's Artists and Machine Learning program* Roland Fischer - Experimental researcher and pharmacologist* Iain McGilchrist - Psychiatrist and author of The Master and His Emissary* William Irwin Thompson - Historian and poet-philosopher* The Tea Faerie - Psychonaut and harm reduction expert* Terence McKenna - Known for his ideas on the Logos and the psychedelic experience* Andrés Gomez Emilsson - Director of Qualia Research Institute focusing on the mathematics of psychedelic experiences* Chris Bledsoe - Known for his family's experiences with entities in a waking state* Stuart Davis - Host of "Aliens and Artists" and known for his encounters with mantis beings* Graham Hancock - Author who encountered "big-brained robots" during a psychedelic experience* Adam Aronovich - Curator of Healing From Healing* Rodney Ascher - Director of the documentary "A Glitch in the Matrix"* Ian McGilchrist - Author and researcher who studies hemispheric specialization in the brain* René Descartes - Philosopher known for his mind-body dualism and views on animals* Helané Wahbeh - Researcher at the Institute of Noetic Sciences, discussed the reproducibility problem in science This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit michaelgarfield.substack.com/subscribe

In this episode, Joe interviews Rick Doblin, Ph.D.: founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), and former board member at Lykos Therapeutics, MAPS' public benefit subsidiary. Doblin tells his side of the story: that the FDA's concerns with double blinding not working had been fully addressed ahead of time, that they had negotiated agreements that were no longer agreed to when new FDA employees came on board, that there was a lot of confusion from going back and forth with the FDA on how Phase 3 studies should be designed, and more. He believes that Lykos made a massive mistake in assuming that provable science was more important than public opinion, and that ignoring critics who were saying whatever they wanted caused them to lose control of the narrative – which clearly influenced the advisory committee. While Lykos figures out their next steps with the FDA, MAPS is focusing their attention on what they feel is most important in light of this ruling: better public education and drug policy. He talks about: How there's a bias at the FDA to be harsh: Does automatically saying no just make it look like you're being rigorous? The work of the Dutch government in researching MDMA, and Lykos' odd decision to not highlight any of it Massachusetts' Legalization and Regulation of Psychedelic Substances initiative, and the huge opportunity for progress at the local level Why federal agents at Burning Man work so hard to give tickets to attendees for smoking cannabis Why sharing stories of your positive experiences with psychedelics is so important and more!  MAPS has announced that 2025's Psychedelic Science conference will be in Denver, June 16-20, and will have experiential opportunities before and after.  For links, head to the show notes page. 

Survivor and advocate Jill Sitnick takes us on a transformative journey as she shares her own powerful story of healing childhood trauma-induced PTSD through psychedelic-assisted psychotherapy. Uncover the myths and misconceptions surrounding psychedelics, often misunderstood as recreational substances, and learn how compounds like psilocybin, MDMA, and LSD are now recognized for their remarkable therapeutic benefits in controlled settings. Jill takes us through her transition from skepticism to advocacy, revealing how MDMA-assisted therapy helped her unlock profound personal growth, opening new doors to healing.Explore the fascinating intersection of somatic experiencing and psychedelic therapy, where emotions are experienced physically, altering long-held perceptions of trauma. Jill's candid account of her journey from the corporate world to embracing psychedelic-assisted coaching provides insight into this emerging therapeutic frontier. Dive into themes of reparenting and Internal Family Systems (IFS), and how these approaches, when paired with psychedelics, can accelerate personal growth and healing, offering a fresh perspective on overcoming entrenched emotional blocks.We navigate the complex legal landscape of psychedelic therapy, highlighting the importance of safety, efficacy, and professional guidance. Delve into Jill's use of MDMA and psilocybin, illustrating the transformative shifts in perception and emotional response they fostered. From the intriguing potential of psychedelics to treat PTSD, depression, anxiety, and chronic pain, to the challenges of gaining FDA approval, this episode promises to equip you with insights and inspiration on the evolving landscape of psychedelic therapy. Join us as we encourage authentic living and curiosity in this ever-evolving field.Connect with Jill:Email: Jill@thejourneysage.comWebsite: https://thejourneysage.com/YouTube: https://www.youtube.com/@TheJourneySageRescuing Jill on Amazon: https://www.amazon.com/Rescuing-Jill-Mushrooms-Childhood-Trauma-Induced/dp/B09X7TTZT7/ref=tmm_pap_swatch_0?_encoding=UTF8&qid=&sr=Additional Resrouces:Clinicaltrials.gov for trial informationMAPS.org (Multidisciplinary Association for Psychedelic Studies) for psychedelic researchSend us a textVisit the Authenticity Road™ website: authenticityroad.onlineConnect with us here.© Authenticity Road, Inc. All rights reserved. Authenticity Road™, its related marks, and "Adventures in men's work" are the exclusive property of Authenticity Road, Inc.

Professor and Investigator Dr. Quevedo is hosted by Jackie Dobrinska for a philosophical talk on interrelation and psychedelic therapies.Today's podcast is brought to you by BetterHelp. Give online therapy a try at betterhelp.com/beherenow and get on your way to being your best self.In this episode, Dr. Sylvestre Quevedo and Jackie Dobrinska explore:The qualities of love within the heartHow the chemical components of MDMA aid in social bonding and heart-openingTouching into transcendent realms and the divineThe importance of our worldviewsNavigating difficult experiences when using plant medicineTurning to sacred texts to glean understandingRam Dass' perspectives on psychedelicsHow the Bhagavad Gita can help usThe Indigenous 7 generation teachingThe efficacy of MDMA in PTSD treatmentAwareness and appreciation for natureThe importance of community and being in connectionThe uses of psychedelics beyond the medical modelThis conversation was recorded as part of the Ram Dass Explorer's club. To learn more and sign up to join a Ram Dass fellowship gathering near you, visit RamDass.org/Fellowship.About Dr. Sylvestre Quevedo:Sylvestre Quevedo is currently Associate Professor of Medicine at UCSF and a Principal Investigator in an FDA trial of MDMA-assisted therapy for PTSD with the Multidisciplinary Association for Psychedelic Studies and UCSF. He earned his medical degree at the Harvard Medical School and a Master of Public Health degree at Harvard School of Public Health. After postdoctoral training in family and community medicine at the University of Arizona, he spent four years developing community health center programs in underserved communities in Colorado, Washington and California. He returned to postdoctoral education with studies in law and public policy at the Stanford Law School, followed by internal medicine at Stanford and a fellowship in nephrology and medicine at Stanford University Medical Center, where he was a Robert Wood Johnson Foundation Clinical Scholar.Learn more about Dr. Quevedo HERE.About Jackie Dobrinska:Jackie Dobrinska is the Director of Education, Community & Inclusion for Ram Dass' Love, Serve, Remember Foundation and the current host of Ram Dass' Here & Now podcast. She is also a teacher, coach, and spiritual director with the privilege of marrying two decades of mystical studies with 15 years of expertise in holistic wellness. As an inter-spiritual minister, Jackie was ordained in Creation Spirituality in 2016 and has also studied extensively in several other lineages – the plant-medicine-based Pachakuti Mesa Tradition, Sri Vidya Tantra, Western European Shamanism, Christian Mysticism, the Wise Woman Tradition, and others. Today, in addition to building courses and community for LSRF, she leads workshops and coaches individuals to discover, nourish and live from their most authentic selves. “The defining characteristic of a medicine carrier is his/her relationship with the medicine. These are not just chemicals or herbs, these are sentient beings that you're in communication with.” – Dr. Sylvestre QuevedoSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Interested in working with Gina? www.ginagratza.comFollow her on Instagram @gina.gratza Gina Gratza is a licensed marriage and family therapist and has spent over a decade supporting individuals, couples, and families through the complexities of trauma, fractured relationships, and personal transformation. She specializes in psychedelic-assisted facilitation, deeply influenced by her work with individuals navigating trauma and eating disorders. Gina is certified in MDMA-Assisted Therapy for PTSD from the Multidisciplinary Association for Psychedelic Studies (MAPS). She is also a ketamine-assisted therapist, trained by the Polaris Insight Center. Gina helped launch the first legal Oregon psilocybin facilitator training school, InnerTrek, and served as Lead Educator and Program Coordinator. Gina is also engaged in psychedelic research with the Social Neuroscience and Psychotherapy Lab as a research study therapist supporting veterans with PTSD. Gina launched a new practice this year centered on women's empowerment. With a variety of group offerings online and in-person, Gina aims to create a community of women who can come together, grow, and heal in the connection. Her practice also supports those navigating and exploring psychedelic spaces. Gina is a seeker, a playful dancer, an embodied woman, and a poet. She continuously moves toward her authentic Self and loves engaging others interested in this dance. 

Based in Florida, Sylvia Benito is a Chartered Financial Analyst (CFA) with more than two decades of portfolio management experience. She has diverse experience in wealth management, having worked as a hedge fund analyst and managing portfolios for family offices and ultra-high-net- worth clients with more than $1 billion in assets.   A thought leader and public speaker committed to helping companies and investors leverage capital for transformative societal impact, Sylvia works with founders, families, and boards to help them align their goals and core values to facilitate positive change on a broader scale.   Also passionate about female empowerment and a believer in the transformative power of psychedelics, Sylvia has spoken at several industry events, including the Multidisciplinary Association for Psychedelic Studies' (MAPS) Psychedelic Science 2023, Women and Wealth, and the Wonderland Conference, where she was a featured speaker with Seano McFarland for "Addiction, Trauma & Psychedelics." Sylvia also spoke at the 39th Private Wealth Management Summit on "Inheritance, Sudden Wealth, and Women," and hosted a fireside chat with Mike Tyson at the National Trial Lawyers Summit in 2023.   In addition to her work in wealth management, Sylvia has experience as an entrepreneur. She co-founded The Oasis Institute in South America, and successfully exited the venture before shifting her focus to investing, with the goal of connecting consciousness to capital. She has been a member of the CFA Society since 2011 and holds a bachelor's degree in Environmental Studies from New College of Florida.     What You'll Learn ●      How to navigate your surroundings and remove the noise. ●      How to create meaning around money. ●      How to balance tradition and innovation.   Timestamps ·       [04:08] Sylvia's training as a Shaman. ·       [08:43] Finding fulfillment and making an impact. ·       [12:43] How to remove the external noise. ·       [17:05] Creating meaning around money. ·       [19:16] Navigating different philosophies. ·       [23:17] Balancing traditions and innovation. ·       [24:38] When to leverage consultants. ·       [27:53] How Sylvia has helped create a higher sense of consciousness. ·       [32:26] How Sylvia got into this work.   Memorable Quotes ·       “There is always this feeling of imposter syndrome.” – Sylvia Benito [07:44] ·       “Meditation ultimately is every moment.” – Sylvia Benito [15:09] ·       “This is a culture of money.” – Sylvia Benito [17:59]   Websites fambizforum.com. www.chrisyonker.com. Sylvia Benito. sylviabenito.com.

Interested in working with Gina? www.ginagratza.comFollow her on Instagram @gina.gratza Gina Gratza is a licensed marriage and family therapist and has spent over a decade supporting individuals, couples, and families through the complexities of trauma, fractured relationships, and personal transformation. She specializes in psychedelic-assisted facilitation, deeply influenced by her work with individuals navigating trauma and eating disorders. Gina is certified in MDMA-Assisted Therapy for PTSD from the Multidisciplinary Association for Psychedelic Studies (MAPS). She is also a ketamine-assisted therapist, trained by the Polaris Insight Center. Gina helped launch the first legal Oregon psilocybin facilitator training school, InnerTrek, and served as Lead Educator and Program Coordinator. Gina is also engaged in psychedelic research with the Social Neuroscience and Psychotherapy Lab as a research study therapist supporting veterans with PTSD. Gina launched a new practice this year centered on women's empowerment. With a variety of group offerings online and in-person, Gina aims to create a community of women who can come together, grow, and heal in the connection. Her practice also supports those navigating and exploring psychedelic spaces. Gina is a seeker, a playful dancer, an embodied woman, and a poet. She continuously moves toward her authentic Self and loves engaging others interested in this dance. 

Could overcoming addiction be as simple as taking a pill?And what if psychedelics could be our gateway into healing mental health and obesity struggles?Today's conversation is nothing short of fascinating.Join me and special guest Mark Haden and Adi Zuloff-Shani from Clearmind Medicine as we dive deep into the current landscape of psychedelics in the health and wellness space.They share about an incredible new molecule that is currently starting clinical trials and showing promising lasting effects on addiction, depression and obesity.Mark Haden Mark Haden is a trailblazer in the field of psychedelic medicine, currently serving as Director of Clinical Research at Psygen and Adjunct Professor at the University of British Columbia School of Population and Public Health. He was a co-founder and spent 10 years as Executive Director of the renowned Multidisciplinary Association for Psychedelic Studies Canada (MAPS). Haden has dedicated the last 30 years to public education and training on drugs and drug policy, including advising the Health Officers Council of British Columbia on the issues of a regulated market for all currently illegal drugs as well as working with Addiction Services in counselling and supervisory roles. He is a frequent keynote speaker and distinguished author on the issues of drug control policy and psychedelics and was awarded the Queen's Diamond Jubilee Medal for his work on drug policy reform in 2013.Adi Zuloff-Shani, PhD Chief Executive Officer at Clearmind MedicineDr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with a vast experience with over 20 years of strategic and operational leadership in the healthcare industry and a deep understanding of therapeutics development in heavily regulated environments. She has expertise in the Pharmaceutical industry, leading cell and drug development through drug and product development, CMC, non-clinical, all stages of clinical development, as well as clinical development strategies and regulatory (FDA, EMEA, others) interactions, NDAs, leading INDs, as well as parallel EU activities. Dr. Zuloff-Shani holds a Ph.D. in human biology and immunology from Bar-Ilan University, Israel.******************Connect with Clearmind Medicine Team:Facebook: https://www.facebook.com/ClearmindMedicine Twitter: https://twitter.com/ClearmindCMND YouTube: https://www.youtube.com/channel/UCg_JDmUZSqstavsbd3zYmmg Instagram: https://www.instagram.com/clearmindmed/ LinkedIn: https://ca.linkedin.com/company/clearmind-medicine ******************➠ Discover the unique ROOT CAUSE that is keeping you stuck on the sugar rollercoaster every year. Take the QUIZ HERE NOW. ➠ Ready to finally kick your emotional eating habit and build a new healthy relationship with sugar from the inside out? Say goodbye to late night snacking and stress eating for good. Get immediate access to my exclusive and FREE Kick Emotional Eating 3 Part Training here. ➠  Want to stay connected and work with Dani during her year off? Come join us in the Sugar Freedom Collective Monthly Community HERE.   ******************Come hang out with me and keep the conversation going on social media:Instagram: https://www.instagram.com/danielleda

Last month, the first psychedelic therapy treatment came before the Food and Drug Administration for a vote. It entailed using MDMA, also known as ecstasy or molly, to treat PTSD.MDMA therapy has looked promising as a treatment for PTSD and other mental health conditions in some studies. But the FDA scientific advisory panel that evaluated this treatment voted overwhelmingly against approving it.Many of the arguments against approval had less to do with MDMA itself than with the methodology of the clinical trials done by Lykos Therapeutics, formerly the Multidisciplinary Association for Psychedelic Studies, or MAPS. The FDA panel was presented with allegations of misconduct and incongruous data, including a letter by trial participant Sarah McNamee.McNamee, who joined the trial for treatment of PTSD, is also a licensed psychotherapist and researcher of trauma and psychotherapy at McGill University in Montreal. She joins guest host Rachel Feltman alongside Dr. Eiko Fried, a methodologist and psychologist at Leiden University in the Netherlands, to discuss the decision.If you or someone you know is struggling with PTSD or other mental health conditions, call 988 for the suicide and crisis lifeline.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Jill Sitnick's journey with PTSD began in her childhood, where she faced severe trauma due to an abusive father and a clinically depressed mother. Despite leaving her tumultuous home life at 19 and building a successful career in educational technology, the unresolved trauma from her past caught up with her in her late forties. After the passing of her long-term partner, Jill experienced severe PTSD attacks that left her feeling suicidal and constantly on high alert. After months of talk therapy without significant improvement, Jill's therapist suggested exploring MDMA-assisted therapy. MDMA, commonly known by its street names ecstasy or molly, is a synthesized chemical that has shown promising results in treating PTSD. Jill was initially skeptical but decided to give it a try after reviewing clinical trial data from the Multidisciplinary Association for Psychedelic Studies (MAPS). The results were nothing short of miraculous. MDMA helped Jill calm her body and mind, allowing her to confront and process her traumatic memories without the overwhelming fear and anxiety that typically accompanied them. Jill's story is a testament to the transformative power of psychedelic-assisted therapy and its potential to offer hope and healing to those suffering from PTSD.   thejourneysage.com

Rick Doblin, Ph.D., is the Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary's Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and puppy, with three empty rooms from his children who have all graduated college and begun their life journeys. Learn more about Rick by listening to his Origin Story and watching his TED Talk.

After much deliberation, this week a panel of experts advising the Food and Drug Administration voted against the approval of therapy-guided MDMA for treating PSTD. Kennedy criticizes the panel for prohibiting PSTD patients from getting effective treatment and highlights the success of studies and clinical trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS) and the high improvement rates reported by participants. Follow Kennedy on Twitter: @KennedyNation Kennedy Now Available on YouTube: https://bit.ly/4311mhD. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Eva Altobelli, MD is the founder of Home-LA. She is a diplomat of the American Board of Psychiatry and Neurology.  Dr. Altobelli holds accreditation from the Multidisciplinary Association of Psychedelic Studies (MAPS) to administer MDMA-assisted therapy for PTSD. She has extensive experience in working with MDMA, psilocybin, and ketamine.  Dr. Altobelli is committed to setting the highest standards of safety, ethics and efficacy.   We discuss topics including: What is ketamine assisted therapy? Understanding professional assisted therapy/aka: “clinician experiential” Psychedelics can increase cognitive and emotional flexibility with eating disorder clients How these types of treatments can support personal and spiritual growth   SHOW NOTES: www.home-la.com www.instagram.com/homela_drevaaltobelli ____________________________________________ If you have any questions regarding the topics discussed on this podcast, please reach out to Robyn directly via email: rlgrd@askaboutfood.com You can also connect with Robyn on social media by following her on Facebook, Instagram, Twitter, and LinkedIn. If you enjoyed this podcast, please leave a review on iTunes and subscribe. Visit Robyn's private practice website where you can subscribe to her free monthly insight newsletter, and receive your FREE GUIDE “Maximizing Your Time with Those Struggling with an Eating Disorder”. Your Recovery Resource, Robyn's new online course for navigating your loved one's eating disorder, is available now! For more information on Robyn's book “The Eating Disorder Trap”, please visit the Official "The Eating Disorder Trap" Website. “The Eating Disorder Trap” is also available for purchase on Amazon.

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture. This week's episode is a crossover roundtable event with our friends at the Multidisciplinary Association for Psychedelic Studies (MAPS) covering the DEA's proposed rescheduling of cannabis from Schedule I to a Schedule III drug. Hosted by our very own Anne Donohoe, the Q&A discussion also features Betty Aldworth, Director of Communications & Post-Prohibition Strategy at MAPS, Karen O'Keefe, Director of State Policies at Marijuana Policy Project (MPP) and Paul Armentano, Deputy Director at NORML.  With the unprecedented federal drug policy change on the near horizon, MAPS assembled leaders with more than 50 years of combined experience in the cannabis policy reform movement to talk about what these changes are, why they matter, what myths need debunking, and what still needs to be done. Some of the topics covered in this conversation include the impact rescheduling will have on research and development of cannabis-based medicines, criminal law and systems-impacted people, cannabis banking and interstate commerce and veteran affairs.  If you are interested in learning more about how MAPS, MPP or NORML have played pivotal roles in implementing drug policy reform over the decades, be sure to follow them all on their socials linked in our show notes and visit their websites to follow their advocacy work.   So, sit back and enjoy this crossover Q&A discussion on the future of cannabis drug policy.  Links and mentions in the show https://maps.org/  https://norml.org/  https://www.mpp.org/  Links to the guest's company and social media accounts Betty Aldworth LinkedIn: https://www.linkedin.com/in/bettyaldworth/  Karen O'Keefe LinkedIn: https://www.linkedin.com/in/karen-o-keefe-255a9921a/  NORML LinkedIn: https://www.linkedin.com/company/norml/  MPP Twitter: https://twitter.com/marijuanapolicy  NORML Twitter: https://twitter.com/NORML  MAPS Twitter: https://twitter.com/maps  Show Credits: This episode was hosted by Anne Donohoe of KCSA Strategic Communications. Special thanks to our Program Director, Shea Gunther and to the MAPS team.  You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels: X: @KCSAPodcastLabs Instagram: @KCSAPodcastLabs LinkedIn: linkedin.com/company/thegreenrushpodcast

The U.S. Food and Drug Administration is reviewing MDMA-assisted therapy for post-traumatic stress disorder, which could become the first psychedelic-assisted therapy as early as August. Today, The Common presents the final episode of our three-part series looking at the past, present and future of psychedelics in Massachusetts as a potential ballot question that could lead to the decriminalization of natural psychedelic substances in Massachusetts. Rick Doblin, founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), is featured in today's conversation. He has led efforts to bring psychedelics back into mainstream medicine, in part by organizing clinical drug trials to get MDMA-assisted therapy for PTSD approved by the FDA. Greater Boston's daily podcast where news and culture meet.

In this episode, Joe interviews Devon Phillips: community & partnerships officer for the Multidisciplinary Association for Psychedelic Studies (MAPS). Phillips works on strategies to tackle the questions: How do we responsibly mainstream psychedelics? And how do we get culture engaged? He's focusing on being the bridge to psychedelics outside of research, facilitating workshops and psychedelic coming-out stories at music festivals and conferences. He talks about harm reduction and drug checking at festivals, the concept of training big names to become trustworthy resources, the differences found in a hop hop crowd compared to EDM, and the power in using psychedelics for pleasure and celebration – not just healing and growth.  He also discusses:  MAPS' involvement with the NFL for their 'My Cause, My Cleats' campaign, and how the San Francisco 49ers' Jon Feliciano is bringing awareness to psychedelic healing Details about MAPS' first responders training, fiscal sponsorship program, international therapist education program, and upcoming membership program (launching in June) The success of MAPS' Psychedelic Science and his hopes for the 2024 edition, taking place June 16 - 20 at the Denver Convention Center Dr. Carl Hart, drug exceptionalism, and the importance of creating safe containers and inclusive drug policy  and more! For links and more, head to the show notes page.

Rick Doblin, founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), chats with Trey Elling. Topics include the potential medicinal benefits of... Intro (0:00) Cannabis (2:16) MDMA (9:55) Ibogaine (24:56) Psilocybin (31:56) Qualified psychedelic therapists (37:32) Total eclipses (42:39)

In today's episode of the Psychedelic Therapy Frontiers, the podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Rick Doblin, Ph.D. Rick is the Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). His tireless efforts over almost 40 years in both clinical research and public policy reform have played a key role in bringing psychedelic medicine to the very exciting point that it is now. They discuss the origin story behind MAPS, the existential crisis humanity is facing and the need for healing on a global scale, the potential FDA approval of MDMA-assisted therapy for PTSD, the “Fallen Mormon” study on the safety of MDMA, the “high bar” that should be set for therapists who work with psychedelic tools, whether or not those therapists should have their own psychedelic experiences as part of their training, and much more.https://maps.org/https://seetexaseclipse.com/Learn more about our podcast at https://numinus.com/podcast/Learn more about psychedelic therapy training opportunities at https://numinus.com/training/Learn more about our clinical trials at https://www.numinus.com/clinical-trials Learn more about Numinus at https://numinus.com/Email us at ptfpodcast@numinus.com Follow us on Instagram: https://www.instagram.com/drstevethayer/https://www.instagram.com/innerspacedoctor/https://www.instagram.com/numinushealth/

Psychedelic drugs have been illegal for 50 years, but they're trickling back into the mainstream because they show promise in helping treat post-traumatic stress disorder and other mental health challenges. We begin the hour with reporter Jonathan A. Davis visiting Psychedelic Science 2023, the largest-ever conference on psychedelic drugs. It's put on by the Multidisciplinary Association for Psychedelic Studies, an organization dedicated to legalizing MDMA (also known as ecstasy or molly) and other psychedelic drugs. Research shows that MDMA-assisted therapy can help treat depression and PTSD, and it's moving toward approval by the U.S. Food and Drug Administration. Psychedelics were studied in the 1950s and '60s as mental health treatments, but the war on drugs put a stop to research. Now, these drugs are gaining bipartisan support from politicians looking for solutions to the mental health crisis among veterans.  Then Reveal's Michael I Schiller visits a group of veterans who are not waiting for psychedelic-assisted therapy to be approved by the federal government. They've joined a church founded by an Iraq War veteran who uses psychedelics as religious sacraments. Schiller accompanies them on a retreat in rural Texas, where they share the depths of their post-traumatic stress and the relief they've felt after psychedelic treatments. He also explores the risks involved in taking these drugs.  We close with an intimate audio diary from a woman in Oakland, California, who's going through therapy with the one psychedelic drug that can be legally prescribed currently in the U.S.: ketamine. Ketamine started out as an anesthetic, but researchers found it can help with treatment-resistant depression when used in tandem with talk therapy. Ketamine can be dangerous if abused, but it also has helped people find relief from mental health issues. This story was produced by Davis.  This is an update of an episode that originally aired in October 2023. Support Reveal's journalism at Revealnews.org/donatenow Subscribe to our weekly newsletter to get the scoop on new episodes at Revealnews.org/newsletter Connect with us on Twitter, Facebook and Instagram Check out independent producer Jonathan A. Davis's work here

Do psychedelics reveal a different objective reality? Neil deGrasse Tyson and Chuck Nice learn about psychedelic drugs, treating PTSD, and other mind-bending research with President of Multidisciplinary Association for Psychedelic Studies (MAPS) Rick Doblin.NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free.Thanks to our Patrons Mark Rosenthal, David Aulwes, Alissa Mc Cormick, Gavin Bamber, Lester Teichner, Chase Kimes, and Cindy Barrick for supporting us this week.Photo Credit: Storyblocks

Psychedelic drugs have been illegal for 50 years, but they're trickling back into the mainstream because they show promise in helping treat post-traumatic stress disorder and other mental health challenges. We begin the hour with reporter Jonathan A. Davis visiting Psychedelic Science 2023, the largest-ever conference on psychedelic drugs. It's put on by the Multidisciplinary Association for Psychedelic Studies, an organization dedicated to legalizing MDMA (also known as ecstasy or molly) and other psychedelic drugs. Research shows that MDMA-assisted therapy can help treat depression and PTSD, and it's moving toward approval by the U.S. Food and Drug Administration. Psychedelics were studied in the 1950s and '60s as mental health treatments, but the war on drugs put a stop to research. Now, these drugs are gaining bipartisan support from politicians looking for solutions to the mental health crisis among veterans.  Then Reveal's Michael I Schiller visits a group of veterans who are not waiting for psychedelic-assisted therapy to be approved by the federal government. They've joined a church founded by an Iraq War veteran who uses psychedelics as religious sacraments. Schiller accompanies them on a retreat in rural Texas, where they share the depths of their post-traumatic stress and the relief they've felt after psychedelic treatments. He also explores the risks involved in taking these drugs.  We close with an intimate audio diary from a woman in Oakland, California, who's going through therapy with the one psychedelic drug that can be legally prescribed currently in the U.S.: ketamine. Ketamine started out as an anesthetic, but researchers found it can help with treatment-resistant depression when used in tandem with talk therapy. Ketamine can be dangerous if abused, but it also has helped people find relief from mental health issues. This story was produced by Davis. Support Reveal's journalism at Revealnews.org/donatenow Subscribe to our weekly newsletter to get the scoop on new episodes at Revealnews.org/newsletter Connect with us on Twitter, Facebook and Instagram Check out independent producer Jonathan A. Davis's work here

Rick Doblin, Ph.D., is the Founder in 1986 and President of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit that wholly owns its pharmaceutical arm, MAPS Public Benefit Corporation (PBC), which has completed two highly successful Phase 3 studies of MDMA-assisted therapy for PTSD. MAPS PBC stands at a crossroads between obtaining the additional resources it needs from philanthropy, ensuring public benefit is foremost, or becoming a publicly traded company.  maps.org